Jaw
Bone Osteogenesis Following Injection of Gel
Containing Bone-Augmenting Agents
The degeneration of alveolar
Bone is a precursor to tooth loss and an ongoing issue for those who already wear dentures. Efforts to regenerate
Bone using
Agents such as recombinant human
Bone morphogenetic protein 2 (BMP-2) have been challenging, since high levels of such growth factors can trigger inflammation and tumorigenesis. Alternatively, a peptide named OP3-4 may inhibit
Bone degeneration and stimulate
Bone forming cell differentiation.
A recent study published in the
Journal of Dental Research by scientists at the Tokyo Medical and Dental University demonstrates the ability of an injectable gelatin-based gel carrying
Bone augmenting
Agents to stimulate
Osteogenesis in alveolar bone. Specifically, a gel carrying OP3-4 and a low concentration of BMP-2 was injected into the jaw bones of preclinical murine models to stimulate localized osteogenesis. The researchers found evidence of regeneration of mineralized
Bone and an increase in
Bone mass around the
Injection site, with a higher
Bone mineral content and density compared to controls.
Overall, the injectable gel carrying these
Bone-Augmenting Agents shows promise as a **n-surgical option for replacing degenerated alveolar
Bone and preventing subsequent tooth loss.
Study in
Journal of Dental Research:
Delivery of RANKL-Binding Peptide OP3-4 Promotes BMP-2–Induced Maxillary Bone Regeneration
Via:*
Tokyo Medical and Dental University
This post
Jaw Bone Osteogenesis Following Injection of Gel Containing Bone-Augmenting Agents appeared first on
Medgadget.
